EVerZom

Private

ParisHealthcare & Life Scienceshttps://everzom.com/

Last Round

Series A

Oct 14, 2025

Total Funding Raised

$18.19M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

EVerZom is a biotechnology company that develops a biomanufacturing platform for exosome-based therapies for regenerative medicine applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

exosome bioproductionbioproduction platformexosome manufacturingexosome therapeuticsextracellular vesiclesregenerative medicineGMP manufacturingmesenchymal stem cellsadvanced therapiesCDMO servicesinflammatory diseasesMSC exosomesCrohn's diseaseco-development partnershipsanimal healthcosmetic applications

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EVerZom Comps

Public and private peers based on sector, stage, and business model.

EVerZom comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

EVerZom Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Oct 14, 2025
Grant	Jun 17, 2025
Grant	Nov 18, 2021
Seed	Nov 30, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Nicolas Rousseau

Co-Founder - COO

Founding Team

Jeanne Volatron

CEO And Co-founder

Founding Team

EVerZom Investors

Notable investors and investment history

EVerZom investors
Investor	Rounds
European Innovation Council	Grant, Series A
Paris Business Angels	Series A
Capital Grand Est	Series A
Sorbonne Venture	Series A
Bpifrance	Grant
Capital Cell	Series A
Aloe Private Equity	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 7, 2026
Monthly visitors grew 579% MoM, reaching 2.3K.
Nov 10, 2025
Monthly visitors increased 253% MoM.

View all signals

EVerZom Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

EVerZom Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EVerZom's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis

Employee Range22

Year Founded2019

Last FundingOct 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.